SCHEMBL2127256

SCHEMBL2127256

O=S(=O)(O)C(c1ccccc1)C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 2/20 0.48
ALDH1A1 P00352 3/20 0.47
ACP1 P24666 1/20 0.42
PTPN7 P35236 1/20 0.42
PTPN12 Q05209 1/20 0.42
PTPN13 Q12923 1/20 0.42
SSU72 Q9NP77 1/20 0.42
TSHR P16473 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
LMNA P02545 3/20 0.38
MAPT P10636 2/20 0.38
KMT2A Q03164 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
KDM4E B2RXH2 1/20 0.38
GMNN O75496 1/20 0.38
POLB P06746 1/20 0.38
HPGD P15428 1/20 0.38
PMP22 Q01453 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16692471 0.83 KMT2A (0.40) SRCALDH1A1ACP1PTPN7PTPN12
SCHEMBL4126232 0.83 CA1 (0.39) SRCALDH1A1MAPTKMT2ANPSR1
SCHEMBL21216561 0.81 CA1 (0.38) SRCALDH1A1LMNAMAPTKMT2A
SCHEMBL4279670 0.79 SRC (0.48) SRCALDH1A1ACP1PTPN7PTPN12
SCHEMBL10622854 0.79 CA1 (0.45) SRCALDH1A1MAPTKMT2ANPSR1
SCHEMBL6673226 0.79 ALDH1A1 (0.36) SRCALDH1A1ACP1PTPN7PTPN12
SCHEMBL27764530 0.79 ALDH1A1 (0.38) SRCALDH1A1ACP1PTPN7PTPN12
SCHEMBL28157857 0.78 SRC (0.47) SRCALDH1A1ACP1PTPN7PTPN12
SCHEMBL4679557 0.74 CA12 (0.37) SRCALDH1A1KMT2AHPGDCA1
Sulfuric Acid SCHEMBL28134621 0.73 SRC (0.42) SRCALDH1A1ACP1PTPN7PTPN12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9452223-B2 Materials and methods relating to glycosylation GLYTHERA LIMITED (GB) 2016-09-27 US claimed
EP-2442831-B9 Materials and methods relating to glycosylation of a therapeutic polypeptide GLYTHERA LTD (GB) 2016-05-11 EP claimed
EP-2442831-B1 Materials and methods relating to glycosylation of a therapeutic polypeptide GLYTHERA LTD (GB) 2015-11-04 EP claimed
US-20120190631-A1 MATERIALS AND METHODS RELATING TO GLYCOSYLATION Iksuda Therapeutics Limited (GB) 2012-07-26 US claimed
EP-2442831-A2 MATERIALS AND METHODS RELATING TO GLYCOSYLATION The University Of Bath (GB) 2012-04-25 EP claimed
WO-2010146362-A2 MATERIALS AND METHODS RELATING TO GLYCOSYLATION THE UNIVERSITY OF BATH (GB) 2010-12-23 WO claimed
US-9996008-B2 Photoresist pattern trimming methods ROHM AND HAAS ELECTRONIC MATERIALS LLC (US) 2018-06-12 US disclosed
US-20170045822-A1 PHOTORESIST PATTERN TRIMMING METHODS U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT 2017-02-16 US disclosed
US-9452223-B2 Materials and methods relating to glycosylation GLYTHERA LIMITED (GB) 2016-09-27 US disclosed
EP-2442831-B9 Materials and methods relating to glycosylation of a therapeutic polypeptide GLYTHERA LTD (GB) 2016-05-11 EP disclosed
EP-2442831-B1 Materials and methods relating to glycosylation of a therapeutic polypeptide GLYTHERA LTD (GB) 2015-11-04 EP disclosed
US-20130171574-A1 PHOTORESIST PATTERN TRIMMING METHODS ROHM AND HAAS ELECTRONIC MATERIALS LLC (US) 2013-07-04 US disclosed
US-20120190631-A1 MATERIALS AND METHODS RELATING TO GLYCOSYLATION Iksuda Therapeutics Limited (GB) 2012-07-26 US disclosed
EP-2442831-A2 MATERIALS AND METHODS RELATING TO GLYCOSYLATION The University Of Bath (GB) 2012-04-25 EP disclosed
WO-2010146362-A2 MATERIALS AND METHODS RELATING TO GLYCOSYLATION THE UNIVERSITY OF BATH (GB) 2010-12-23 WO disclosed
EP-1718605-B1 PROCESSES FOR THE PREPARATION OF ARYL-AND HETEROARYL-ALKYLSULFONYL HALIDES WYETH CORP (US) 2009-06-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190631-A1 MATERIALS AND METHODS RELATING TO GLYCOSYLATION NEU3, FUT5, NEU2 SRC 1383/4885ALDH1A1 731/4885ACP1 233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.